Top Hormonal Contraceptives Companies

Global Hormonal Contraceptives Market size was valued at USD 17.84 Billion in 2024 and is poised to grow from USD 18.6 Billion in 2025 to USD 26.05 Billion by 2033, growing at a CAGR of 4.3% in the forecast period (2026–2033).

To remain competitive in the Hormonal Contraceptives Market, major manufacturers focus on regulatory compliance, product innovation, and expanding access through partnership. The key payers invest in research & development in order to develop advanced formulations such as long-acting injectables which increase production processes to meet the regulatory standard. Acquisition and mergers also drive the market expansion. With the increasing demand for non-oral options among consumers, various companies are diversifying their product portfolio and enhancing their sustainability efforts. 'AbbVie', 'Bayer', 'Pfizer Inc.', 'Merck & Co., Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Mylan N.V. (Viatris Inc.)', 'Allergan plc', 'Johnson & Johnson', 'Agile Therapeutics', 'Organon Group', 'Afaxys, Inc.', 'HRA Pharma', 'Piramal Enterprises Ltd.', 'Novartis AG', 'GlaxoSmithKline plc', 'Dr. Reddy's Laboratories Ltd.', 'Cupid Limited', 'Lupin Pharmaceuticals, Inc.', 'Theramex', 'Evotec SE', ' '

The increase in awareness about family planning, coupled with rising female education levels are one of the key factors for the growth of the market. The Family Planning 2030 (FP2030) aims to enable nearly 120 million women and girls to access modern contraceptive in middle- and low-income countries. As of 2023, nearly 370 million women were using modern contraceptive, with hormonal methods, such as injectables and orals pills, globally.

Short-Term: The rapid digital transformation in contraceptive industry with the launch of various app-based prescription services and telemedicine is making hormonal contraceptive user friendly. The increasing demand for convenience and privacy mostly among millennial and Gen Z, the healthcare providers are adopting digital platforms for prescription management, compliance tracking and improve consultancy. These developments are increasing the adherence rate and user satisfaction.

In 2024, Asia Pacific dominates the hormonal contraceptives market owing to its large reproductive age population, surge in government initiatives which support reproductive health and rise in awareness of family planning. Countries like China and India are witnessing increasing adoption due to advancement in healthcare infrastructure, and availability of contraceptive products to consumers through private and public channels. The increasing female workforce participation and urbanization propel the growth of the market.